CompletedNCT02476058
A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder
Researchers compared JNJ-42847922, Diphenhydramine and placebo, tracking side effects to assess safety and tolerability in people with depression.
Medication studyAges 18–64Multiple countries
Understand this study
What did researchers investigate?
Researchers compared JNJ-42847922, Diphenhydramine and placebo, tracking side effects to assess safety and tolerability in people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Aalst and 6 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: June 11, 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 48
- Sponsor
- Janssen-Cilag International NV
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Belgium, Germany, Netherlands
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT02476058
- Official title
Show the full official title
An Exploratory Multicenter, Double-Blind, Diphenhydramine- and Placebo-Controlled Safety, Efficacy and Biomarker Study With JNJ-42847922 in Subjects With Major Depressive Disorder
Recruitment & locations
CompletedAalst, Belgium · Brussels, Belgium · Duffel, Belgium
4 more locations
- Berlin, Germany
- Hamburg, Germany
- Schwerin, Germany
- Leiden, Netherlands
Questions about this study
What did researchers investigate?
Researchers compared JNJ-42847922, Diphenhydramine and placebo, tracking side effects to assess safety and tolerability in people with depression.
Who is behind this study?
The study sponsor is Janssen-Cilag International NV.
Did this study involve medication?
Yes. The study involved medication, including JNJ-42847922, Diphenhydramine and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicide prevention, in Adult Participants Assessed to be at Imminent Risk for Suicide
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicide prevention, in Adult Participants Assessed to be at Imminent Risk for Suicide